ASPIC

Virtual event, Worldwide

22-23 February, 2022

See more informations here: https://www.eacr.org/conference/structuralmicroenv2022virtual/index?utm_source=eacrnews&utm_medium=email&utm_campaign=vSM22&utm_content=

Virtual Event, Worldwide

07-08 December, 2021

See more informations here: https://www.eacr.org/conference/astrazeneca2021virtual?utm_source=eacrnews&utm_medium=email&utm_campaign=vAZ21

Virtual Event, Worldwide

07-08 December, 2021

See more informations here: https://www.eacr.org/conference/astrazeneca2021virtual?utm_source=eacrnews&utm_medium=email&utm_campaign=vAZ21

On-line event

25-26 January, 2022

See more informations here: https://www.eacr.org/conference/seedandsoil2022/index

On-line event

25-26 January, 2022

See more informations here: https://www.eacr.org/conference/seedandsoil2022/index

Over 70% of breast cancers (BC) are estrogen receptor-positive (ER+). The Notch ligand Delta-like 1 (DLL1) is a key player in ER+ BCs development and aggressiveness and its overexpression are associated with poor prognosis. In this study, Portuguese researchers developed a novel anti-DLL1 antibody that inhibited tumor growth and liver metastases in a xenograft mouse model. The data suggests that anti-DLL1 immunotherapy can be a promising strategy for ER+ BC treatment.

Authors and Affiliations:

Mais de 70% dos cancros da mama são positivos para o recetor de estrogénio (ER+ BC). A expressão elevada da proteína DLL1 nestes tumores está associada a maior agressividade e por conseguinte a pior prognóstico. Neste estudo, investigadores portugueses desenvolveram um anticorpo capaz de impedir a formação de metástases hepáticas em modelos animais xenotransplantados. Este estudo sugere a inibição da proteína DLL1 como uma nova abordagem no tratamento de cancros da mama positivos para o recetor de estrogénio.

Autores e afiliações:

Cervical cancer (CC) is considered the 4^th most common cause of death in women worldwide, with over 99% of cases related to human papilloma virus (HPV) infection. According to data from Globocan, in 2020, there were 341 831 deaths, with a higher incidence in developing countries, mainly due to limited financial resources and access to health care. The development of this pathology is related to the expression of the HPV E6 and E7 proteins, since they can interfere with the cellular regulatory mechanisms potentiated by tumor suppressor proteins, such as p53 and pRB proteins.

O cancro do colo do útero (CCU) é considerado a 4º causa mais comum de morte em mulheres em todo o mundo, com mais de 99% dos casos relacionados com infeção pelo papiloma vírus humano (HPV). De acordo com os dados do Globocan, em 2020, ocorreram 341 831 mortes observando-se uma maior incidência em países em desenvolvimento devido principalmente ao limite de recursos financeiros e acesso a cuidados de saúde.

Authors and Affiliations:

Inês Direito¹, Liliana Monteiro¹, Tânia Melo², Daniela Figueira¹, João Lobo^3,4,5, Vera Enes¹, Gabriela Moura¹, Rui Henrique^3,4,5, Manuel A. S. Santos¹, Carmen Jerónimo^3,4,5, Francisco Amado², Margarida Fardilha¹ e Luisa A. Helguero¹

¹ iBiMED—Institute of Biomedicine, Universidade de Aveiro, 3810-193 Aveiro, Portugal;